MONTCO Today on MSN7 小时
Plymouth Meeting’s Harmony Biosciences Eyes $3B in Sales with New Treatments on the Way
Since launching in 2017, Plymouth Meeting’s Harmony Biosciences has grown from a small drug developer into a billion-dollar ...
Deutsche Bank sets Alkermes stock Buy rating, $40 target
Deutsche Bank (ETR:DBKGn) initiated coverage on Alkermes (NASDAQ:ALKS) shares with a Buy rating and a price target of $40.00. The firm's analysts highlighted the company's promising drug, ALKS 2680, ...